Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade
Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had...
Gespeichert in:
Veröffentlicht in: | Journal of the American Society of Nephrology 2006-12, Vol.17 (12 Suppl 3), p.S206-S212 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | S212 |
---|---|
container_issue | 12 Suppl 3 |
container_start_page | S206 |
container_title | Journal of the American Society of Nephrology |
container_volume | 17 |
creator | GARCIA DE VINUESA, Soledad GOICOECHEA, Marian KANTER, Julia PUERTA, Marta CACHOFEIRO, Victoria LAHERA, Vicente GOMEZ-CAMPDERA, Francisco LUNO, José |
description | Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had stages 3 and 4 CKD and no diabetes were administered an angiotensin receptor blocker (ARB), olmesartan (40 mg), for 16 wk. Before and after ARB treatment, metabolic and inflammatory parameters and adipokines were measured. IR was calculated by Homeostasis Model Assessment (HOMA) index. Baseline data were compared with data that were obtained from 25 healthy control individuals of similar age and normal renal function. Compared with control subjects, patients with CKD presented significantly higher BP and waist circumference, higher triglycerides and lower HDL levels, higher insulin levels, and higher mean HOMA index (6.0 +/- 2.7 versus 2.9 +/- 2.2 muU/ml x mmol/L; P < 0.001). In addition, patients with CKD had increased levels of high-sensitivity C-reactive protein, TNF-alpha, and IL-6. In patients with CKD, leptin was positively correlated to abdominal obesity, insulin levels, and IL-6, and adiponectin was inversely correlated to abdominal obesity and insulin levels. Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 +/- 16 versus 92 +/- 14 mg/dl; P < 0.05), insulin (23.1 +/- 8.8 versus 19.9 +/- 9; P < 0.05), HOMA index (6.0 +/- 2.7 versus 4.7 +/- 2.8; P < 0.05), and glycated hemoglobin (5.33 +/- 0.58 versus 4.85 +/- 0.81%; P < 0.01). At the same time, there was a significant reduction of high-sensitivity C-reactive protein levels, from 4.45 mg/L (2.45 to 9.00) to 3.55 mg/L (1.80 to 5.40; P < 0.05) and fibrinogen (412 +/- 100 versus 370 +/- 105 mg/dl; P < 0.05). There were no significant differences in adipokine levels after olmesartan treatment. These data demonstrate that patients with CKD have a high prevalence of IR, metabolic syndrome, and chronic inflammation and that the administration of the ARB olmesartan improves IR and inflammation markers in these patients. Plasma adipokine levels that are related to several metabolic risk factors in patients with CKD were not modified by ARB therapy. |
doi_str_mv | 10.1681/ASN.2006080916 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68185586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68185586</sourcerecordid><originalsourceid>FETCH-LOGICAL-c278t-8795269f4d0eb87254c60b7069cc87eb85c61d6a44755d98bbffc83c664da8a3</originalsourceid><addsrcrecordid>eNpFkT1vFDEQhq2IKF_QUiI3UGUPe73-WLooSuCkKBRJv_LaY2Ju1z48e0L3D_KzMcpJV81o9Lxv8QwhHzlbcWX415unx1XLmGKG9VydkAsuhWhEJ9m7urNONUppcU4uEX8zxmWr9Rk555oL1ipxQV7XCXdTTLQARlxscnBNYwqTnWe75LKnY8yzLRsoeE1t8tT6uM2bmAArR7d2iZAWpH_j8kLdS8kpOrqJPsGe-ohgEeg3ehcCuErlUDt-xbxAwpper-k4ZbexHt6T02AnhA-HeUWe7--eb380Dz-_r29vHhrXarM0RveyVX3oPIPR6FZ2TrFRM9U7Z3Q9Sae4V7brtJS-N-MYgjPCKdV5a6y4Il_earcl_9kBLsMc0cE02QR5h0N1aqQ0qoKrN9CVjFggDNsSq4j9wNnwX_1Q1Q9H9TXw6dC8G2fwR_zgugKfD4BFZ6dQquyIR86I-p2uF_8AbGiNtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68185586</pqid></control><display><type>article</type><title>Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GARCIA DE VINUESA, Soledad ; GOICOECHEA, Marian ; KANTER, Julia ; PUERTA, Marta ; CACHOFEIRO, Victoria ; LAHERA, Vicente ; GOMEZ-CAMPDERA, Francisco ; LUNO, José</creator><creatorcontrib>GARCIA DE VINUESA, Soledad ; GOICOECHEA, Marian ; KANTER, Julia ; PUERTA, Marta ; CACHOFEIRO, Victoria ; LAHERA, Vicente ; GOMEZ-CAMPDERA, Francisco ; LUNO, José</creatorcontrib><description><![CDATA[Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had stages 3 and 4 CKD and no diabetes were administered an angiotensin receptor blocker (ARB), olmesartan (40 mg), for 16 wk. Before and after ARB treatment, metabolic and inflammatory parameters and adipokines were measured. IR was calculated by Homeostasis Model Assessment (HOMA) index. Baseline data were compared with data that were obtained from 25 healthy control individuals of similar age and normal renal function. Compared with control subjects, patients with CKD presented significantly higher BP and waist circumference, higher triglycerides and lower HDL levels, higher insulin levels, and higher mean HOMA index (6.0 +/- 2.7 versus 2.9 +/- 2.2 muU/ml x mmol/L; P < 0.001). In addition, patients with CKD had increased levels of high-sensitivity C-reactive protein, TNF-alpha, and IL-6. In patients with CKD, leptin was positively correlated to abdominal obesity, insulin levels, and IL-6, and adiponectin was inversely correlated to abdominal obesity and insulin levels. Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 +/- 16 versus 92 +/- 14 mg/dl; P < 0.05), insulin (23.1 +/- 8.8 versus 19.9 +/- 9; P < 0.05), HOMA index (6.0 +/- 2.7 versus 4.7 +/- 2.8; P < 0.05), and glycated hemoglobin (5.33 +/- 0.58 versus 4.85 +/- 0.81%; P < 0.01). At the same time, there was a significant reduction of high-sensitivity C-reactive protein levels, from 4.45 mg/L (2.45 to 9.00) to 3.55 mg/L (1.80 to 5.40; P < 0.05) and fibrinogen (412 +/- 100 versus 370 +/- 105 mg/dl; P < 0.05). There were no significant differences in adipokine levels after olmesartan treatment. These data demonstrate that patients with CKD have a high prevalence of IR, metabolic syndrome, and chronic inflammation and that the administration of the ARB olmesartan improves IR and inflammation markers in these patients. Plasma adipokine levels that are related to several metabolic risk factors in patients with CKD were not modified by ARB therapy.]]></description><identifier>ISSN: 1046-6673</identifier><identifier>EISSN: 1533-3450</identifier><identifier>DOI: 10.1681/ASN.2006080916</identifier><identifier>PMID: 17130263</identifier><identifier>CODEN: JASNEU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adipokines - blood ; Adiponectin - blood ; Adult ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers - therapeutic use ; Biological and medical sciences ; C-Reactive Protein - metabolism ; Chronic Disease ; Female ; Humans ; Imidazoles - therapeutic use ; Inflammation - blood ; Insulin - blood ; Insulin Resistance - physiology ; Interleukin-6 - blood ; Kidney Diseases - blood ; Kidney Diseases - drug therapy ; Kidney Diseases - physiopathology ; Kidneys ; Leptin - blood ; Male ; Medical sciences ; Metabolic Syndrome - blood ; Metabolic Syndrome - physiopathology ; Middle Aged ; Nephrology. Urinary tract diseases ; Olmesartan Medoxomil ; Pharmacology. Drug treatments ; Tetrazoles - therapeutic use ; Urinary system ; Urinary system involvement in other diseases. Miscellaneous ; Waist-Hip Ratio</subject><ispartof>Journal of the American Society of Nephrology, 2006-12, Vol.17 (12 Suppl 3), p.S206-S212</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18352749$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17130263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GARCIA DE VINUESA, Soledad</creatorcontrib><creatorcontrib>GOICOECHEA, Marian</creatorcontrib><creatorcontrib>KANTER, Julia</creatorcontrib><creatorcontrib>PUERTA, Marta</creatorcontrib><creatorcontrib>CACHOFEIRO, Victoria</creatorcontrib><creatorcontrib>LAHERA, Vicente</creatorcontrib><creatorcontrib>GOMEZ-CAMPDERA, Francisco</creatorcontrib><creatorcontrib>LUNO, José</creatorcontrib><title>Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade</title><title>Journal of the American Society of Nephrology</title><addtitle>J Am Soc Nephrol</addtitle><description><![CDATA[Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had stages 3 and 4 CKD and no diabetes were administered an angiotensin receptor blocker (ARB), olmesartan (40 mg), for 16 wk. Before and after ARB treatment, metabolic and inflammatory parameters and adipokines were measured. IR was calculated by Homeostasis Model Assessment (HOMA) index. Baseline data were compared with data that were obtained from 25 healthy control individuals of similar age and normal renal function. Compared with control subjects, patients with CKD presented significantly higher BP and waist circumference, higher triglycerides and lower HDL levels, higher insulin levels, and higher mean HOMA index (6.0 +/- 2.7 versus 2.9 +/- 2.2 muU/ml x mmol/L; P < 0.001). In addition, patients with CKD had increased levels of high-sensitivity C-reactive protein, TNF-alpha, and IL-6. In patients with CKD, leptin was positively correlated to abdominal obesity, insulin levels, and IL-6, and adiponectin was inversely correlated to abdominal obesity and insulin levels. Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 +/- 16 versus 92 +/- 14 mg/dl; P < 0.05), insulin (23.1 +/- 8.8 versus 19.9 +/- 9; P < 0.05), HOMA index (6.0 +/- 2.7 versus 4.7 +/- 2.8; P < 0.05), and glycated hemoglobin (5.33 +/- 0.58 versus 4.85 +/- 0.81%; P < 0.01). At the same time, there was a significant reduction of high-sensitivity C-reactive protein levels, from 4.45 mg/L (2.45 to 9.00) to 3.55 mg/L (1.80 to 5.40; P < 0.05) and fibrinogen (412 +/- 100 versus 370 +/- 105 mg/dl; P < 0.05). There were no significant differences in adipokine levels after olmesartan treatment. These data demonstrate that patients with CKD have a high prevalence of IR, metabolic syndrome, and chronic inflammation and that the administration of the ARB olmesartan improves IR and inflammation markers in these patients. Plasma adipokine levels that are related to several metabolic risk factors in patients with CKD were not modified by ARB therapy.]]></description><subject>Adipokines - blood</subject><subject>Adiponectin - blood</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiotensin II Type 1 Receptor Blockers - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>C-Reactive Protein - metabolism</subject><subject>Chronic Disease</subject><subject>Female</subject><subject>Humans</subject><subject>Imidazoles - therapeutic use</subject><subject>Inflammation - blood</subject><subject>Insulin - blood</subject><subject>Insulin Resistance - physiology</subject><subject>Interleukin-6 - blood</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - physiopathology</subject><subject>Kidneys</subject><subject>Leptin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolic Syndrome - blood</subject><subject>Metabolic Syndrome - physiopathology</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Olmesartan Medoxomil</subject><subject>Pharmacology. Drug treatments</subject><subject>Tetrazoles - therapeutic use</subject><subject>Urinary system</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Waist-Hip Ratio</subject><issn>1046-6673</issn><issn>1533-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkT1vFDEQhq2IKF_QUiI3UGUPe73-WLooSuCkKBRJv_LaY2Ju1z48e0L3D_KzMcpJV81o9Lxv8QwhHzlbcWX415unx1XLmGKG9VydkAsuhWhEJ9m7urNONUppcU4uEX8zxmWr9Rk555oL1ipxQV7XCXdTTLQARlxscnBNYwqTnWe75LKnY8yzLRsoeE1t8tT6uM2bmAArR7d2iZAWpH_j8kLdS8kpOrqJPsGe-ohgEeg3ehcCuErlUDt-xbxAwpper-k4ZbexHt6T02AnhA-HeUWe7--eb380Dz-_r29vHhrXarM0RveyVX3oPIPR6FZ2TrFRM9U7Z3Q9Sae4V7brtJS-N-MYgjPCKdV5a6y4Il_earcl_9kBLsMc0cE02QR5h0N1aqQ0qoKrN9CVjFggDNsSq4j9wNnwX_1Q1Q9H9TXw6dC8G2fwR_zgugKfD4BFZ6dQquyIR86I-p2uF_8AbGiNtw</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>GARCIA DE VINUESA, Soledad</creator><creator>GOICOECHEA, Marian</creator><creator>KANTER, Julia</creator><creator>PUERTA, Marta</creator><creator>CACHOFEIRO, Victoria</creator><creator>LAHERA, Vicente</creator><creator>GOMEZ-CAMPDERA, Francisco</creator><creator>LUNO, José</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade</title><author>GARCIA DE VINUESA, Soledad ; GOICOECHEA, Marian ; KANTER, Julia ; PUERTA, Marta ; CACHOFEIRO, Victoria ; LAHERA, Vicente ; GOMEZ-CAMPDERA, Francisco ; LUNO, José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c278t-8795269f4d0eb87254c60b7069cc87eb85c61d6a44755d98bbffc83c664da8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adipokines - blood</topic><topic>Adiponectin - blood</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiotensin II Type 1 Receptor Blockers - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>C-Reactive Protein - metabolism</topic><topic>Chronic Disease</topic><topic>Female</topic><topic>Humans</topic><topic>Imidazoles - therapeutic use</topic><topic>Inflammation - blood</topic><topic>Insulin - blood</topic><topic>Insulin Resistance - physiology</topic><topic>Interleukin-6 - blood</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - physiopathology</topic><topic>Kidneys</topic><topic>Leptin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolic Syndrome - blood</topic><topic>Metabolic Syndrome - physiopathology</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Olmesartan Medoxomil</topic><topic>Pharmacology. Drug treatments</topic><topic>Tetrazoles - therapeutic use</topic><topic>Urinary system</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Waist-Hip Ratio</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GARCIA DE VINUESA, Soledad</creatorcontrib><creatorcontrib>GOICOECHEA, Marian</creatorcontrib><creatorcontrib>KANTER, Julia</creatorcontrib><creatorcontrib>PUERTA, Marta</creatorcontrib><creatorcontrib>CACHOFEIRO, Victoria</creatorcontrib><creatorcontrib>LAHERA, Vicente</creatorcontrib><creatorcontrib>GOMEZ-CAMPDERA, Francisco</creatorcontrib><creatorcontrib>LUNO, José</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Society of Nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GARCIA DE VINUESA, Soledad</au><au>GOICOECHEA, Marian</au><au>KANTER, Julia</au><au>PUERTA, Marta</au><au>CACHOFEIRO, Victoria</au><au>LAHERA, Vicente</au><au>GOMEZ-CAMPDERA, Francisco</au><au>LUNO, José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade</atitle><jtitle>Journal of the American Society of Nephrology</jtitle><addtitle>J Am Soc Nephrol</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>17</volume><issue>12 Suppl 3</issue><spage>S206</spage><epage>S212</epage><pages>S206-S212</pages><issn>1046-6673</issn><eissn>1533-3450</eissn><coden>JASNEU</coden><abstract><![CDATA[Patients with chronic kidney disease (CKD) present a high prevalence of insulin resistance (IR). Some studies suggest that angiotensin II may influence some cellular pathways that contribute to the pathogenesis of IR and stimulate the release of proinflammatory cytokines. Fifty-two patients who had stages 3 and 4 CKD and no diabetes were administered an angiotensin receptor blocker (ARB), olmesartan (40 mg), for 16 wk. Before and after ARB treatment, metabolic and inflammatory parameters and adipokines were measured. IR was calculated by Homeostasis Model Assessment (HOMA) index. Baseline data were compared with data that were obtained from 25 healthy control individuals of similar age and normal renal function. Compared with control subjects, patients with CKD presented significantly higher BP and waist circumference, higher triglycerides and lower HDL levels, higher insulin levels, and higher mean HOMA index (6.0 +/- 2.7 versus 2.9 +/- 2.2 muU/ml x mmol/L; P < 0.001). In addition, patients with CKD had increased levels of high-sensitivity C-reactive protein, TNF-alpha, and IL-6. In patients with CKD, leptin was positively correlated to abdominal obesity, insulin levels, and IL-6, and adiponectin was inversely correlated to abdominal obesity and insulin levels. Olmesartan treatment resulted in a significant decrease of BP, urinary protein excretion, plasma glucose (99 +/- 16 versus 92 +/- 14 mg/dl; P < 0.05), insulin (23.1 +/- 8.8 versus 19.9 +/- 9; P < 0.05), HOMA index (6.0 +/- 2.7 versus 4.7 +/- 2.8; P < 0.05), and glycated hemoglobin (5.33 +/- 0.58 versus 4.85 +/- 0.81%; P < 0.01). At the same time, there was a significant reduction of high-sensitivity C-reactive protein levels, from 4.45 mg/L (2.45 to 9.00) to 3.55 mg/L (1.80 to 5.40; P < 0.05) and fibrinogen (412 +/- 100 versus 370 +/- 105 mg/dl; P < 0.05). There were no significant differences in adipokine levels after olmesartan treatment. These data demonstrate that patients with CKD have a high prevalence of IR, metabolic syndrome, and chronic inflammation and that the administration of the ARB olmesartan improves IR and inflammation markers in these patients. Plasma adipokine levels that are related to several metabolic risk factors in patients with CKD were not modified by ARB therapy.]]></abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>17130263</pmid><doi>10.1681/ASN.2006080916</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1046-6673 |
ispartof | Journal of the American Society of Nephrology, 2006-12, Vol.17 (12 Suppl 3), p.S206-S212 |
issn | 1046-6673 1533-3450 |
language | eng |
recordid | cdi_proquest_miscellaneous_68185586 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Adipokines - blood Adiponectin - blood Adult Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers - therapeutic use Biological and medical sciences C-Reactive Protein - metabolism Chronic Disease Female Humans Imidazoles - therapeutic use Inflammation - blood Insulin - blood Insulin Resistance - physiology Interleukin-6 - blood Kidney Diseases - blood Kidney Diseases - drug therapy Kidney Diseases - physiopathology Kidneys Leptin - blood Male Medical sciences Metabolic Syndrome - blood Metabolic Syndrome - physiopathology Middle Aged Nephrology. Urinary tract diseases Olmesartan Medoxomil Pharmacology. Drug treatments Tetrazoles - therapeutic use Urinary system Urinary system involvement in other diseases. Miscellaneous Waist-Hip Ratio |
title | Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease : Effects of angiotensin II blockade |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T02%3A24%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin%20resistance,%20inflammatory%20biomarkers,%20and%20adipokines%20in%20patients%20with%20chronic%20kidney%20disease%20:%20Effects%20of%20angiotensin%20II%20blockade&rft.jtitle=Journal%20of%20the%20American%20Society%20of%20Nephrology&rft.au=GARCIA%20DE%20VINUESA,%20Soledad&rft.date=2006-12-01&rft.volume=17&rft.issue=12%20Suppl%203&rft.spage=S206&rft.epage=S212&rft.pages=S206-S212&rft.issn=1046-6673&rft.eissn=1533-3450&rft.coden=JASNEU&rft_id=info:doi/10.1681/ASN.2006080916&rft_dat=%3Cproquest_cross%3E68185586%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68185586&rft_id=info:pmid/17130263&rfr_iscdi=true |